Want to see ALPS full AI Analyst Report?
ALPS Group (ALPS) Stock Price & Analysis
ALPS Stock Chart & Stats
- Day’s Range
- $0.32 - $0.33
- 52-Week Range
- $0.23 - $2.90
- Previous Close
- $0.32
- Volume
- N/A
- Average Volume (3M)
- 39.50K
- Market Cap
- $54.08M
- Enterprise Value
- $121.70T
- Total Cash (Recent Filing)
- $357.73K
- Total Debt (Recent Filing)
- $5.91M
- Price to Earnings (P/E)
- ―
- Beta
- 0.30
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Feb 13, 2023
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
The 44% revenue increase shows that Alps is expanding across several operating businesses rather than relying on a single activity. Continued growth in therapy, testing, laboratory and aesthetics services could broaden the commercial base and support greater scale over the next several quarters.
Focused Platform Strategy
Concentrating resources on priority programs can improve execution by reducing distractions and directing research spending toward platforms with greater strategic relevance. Progress in NK-cell and exosome programs may strengthen the company’s longer-term precision-medicine positioning if development continues.
Expanded Diagnostic Capabilities
Whole genome sequencing accreditation and the planned organoid platform expand Alps’ capabilities across diagnostics and translational research. These assets can deepen its integrated healthcare offering, support more sophisticated testing and create additional opportunities within regional precision medicine.
Bears Say
Persistent Losses
Revenue growth has not yet translated into sustainable profitability, as deeply negative net margins and continuing operating losses show that the business remains economically pressured. Without improvement in operating leverage or gross margin, future expansion may continue requiring external financial support.
Ongoing Cash Burn
Negative operating and free cash flow mean Alps is not currently self-funding its activities, even though free cash flow improved year over year. Continued cash outflows can constrain investment in growth programs and increase reliance on future financing to sustain operations.
Negative Equity And Leverage Risk
The shift from positive equity in 2024 to negative equity in 2025 and 2026 materially weakens the capital structure. Combined with sizeable debt, this reduces financial flexibility and can make it harder to absorb setbacks or fund strategic initiatives on favorable terms.
ALPS Group News
ALPS FAQ
What was ALPS Group’s price range in the past 12 months?
What is ALPS Group’s market cap?
When is ALPS Group’s upcoming earnings report date?
How were ALPS Group’s earnings last quarter?
Is ALPS Group overvalued?
Does ALPS Group pay dividends?
What is ALPS Group’s EPS estimate?
How many shares outstanding does ALPS Group have?
What happened to ALPS Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ALPS Group?
What is the TipRanks Smart Score and how is it calculated?
Company Description
ALPS Group
Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-edge therapeutic solutions. The organization is committed to cultivating a just and balanced healthcare system, ensuring broad availability of early detection, disease prevention, and individualized treatment approaches.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Seng Kong Tham
- Employees
- 93
- Website
- alps-holdings.com
- Address
- The ICON, East Wing Tower, Level 18-01 & 18-02, No.1, Jalan 1/68F, Off Jalan Tun Razak, Kuala Lumpur, WP, 50400, MY
ALPS Group (ALPS) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |







